These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 1547417)

  • 41. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients.
    Cody J; Daly C; Campbell M; Donaldson C; Grant A; Khan I; Pennington S; Vale L; Wallace S; MacLeod A
    Cochrane Database Syst Rev; 2001; (4):CD003266. PubMed ID: 11687180
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients.
    Frenken LA; Verberckmoes R; Michielsen P; Koene RA
    Nephrol Dial Transplant; 1989; 4(9):782-6. PubMed ID: 2516609
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
    Riedel MK; Morgenstern T
    Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Proposed therapeutic algorithm for the treatment of anemia of chronic renal failure in pre-dialysis patients with low dose once weekly subcutaneous r-HuEPO. Multicenter Study Group, Israel.
    Yagil Y
    Isr J Med Sci; 1997 Jan; 33(1):36-44. PubMed ID: 9203516
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravenous calcitriol improves anaemia and reduces the need for erythropoietin in haemodialysis patients.
    Goicoechea M; Vazquez MI; Ruiz MA; Gomez-Campdera F; Perez-García R; Valderrábano F
    Nephron; 1998; 78(1):23-7. PubMed ID: 9453399
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Erythropoietin requirements increase following hospitalization in end-stage renal disease patients.
    Yaqub MS; Leiser J; Molitoris BA
    Am J Nephrol; 2001; 21(5):390-6. PubMed ID: 11684801
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Single weekly dose of recombinant erythropoietin in children with chronic renal insufficiency].
    Guízar JM; Gutiérrez MJ; Sánchez G; Kornhauser C
    Rev Invest Clin; 1996; 48(3):173-7. PubMed ID: 8966377
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recombinant human erythropoietin therapy in children maintained by haemodialysis.
    Rigden SP; Montini G; Morris M; Clark KG; Haycock GB; Chantler C; Hill RC
    Pediatr Nephrol; 1990 Nov; 4(6):618-22. PubMed ID: 2088464
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of recombinant human erythropoietin on medical care costs for hemodialysis patients in Canada.
    Sheingold S; Churchill D; Muirhead N; Laupacis A; Labelle R; Goeree R
    Soc Sci Med; 1992 May; 34(9):983-91. PubMed ID: 1631611
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The treatment of anemia with low-dose recombinant human erythropoietin.
    Aronoff GR; Duff DR; Sloan RS; Brier ME; Maurice B; Erickson B; Golper TA
    Am J Nephrol; 1990; 10 Suppl 2():40-3. PubMed ID: 2260617
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
    Yong K; Kairaitis L
    Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Therapy of renal anemia with recombinant human erythropoietin].
    Schaefer RM; Kürner B; Zech M; Krahn R; Heidland A
    Dtsch Med Wochenschr; 1988 Jan; 113(4):125-9. PubMed ID: 3276487
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.
    Collins AJ; Monda KL; Molony JT; Li S; Gilbertson DT; Bradbury BD
    Am J Kidney Dis; 2014 Jun; 63(6):997-1006. PubMed ID: 24315770
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A prospective crossover trial comparing intermittent intravenous and continuous oral iron supplements in peritoneal dialysis patients.
    Johnson DW; Herzig KA; Gissane R; Campbell SB; Hawley CM; Isbel NM
    Nephrol Dial Transplant; 2001 Sep; 16(9):1879-84. PubMed ID: 11522873
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Cost minimisation analysis for darbepoetin alpha vs. epoetin alpha in chronic kidney disease patients on haemodialysis].
    Cuesta Grueso C; Poveda Andrés JL; Garcia Pellicer J; Romá Sánchez E
    Farm Hosp; 2010; 34(2):68-75. PubMed ID: 20206567
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Treatment of anemia in hemodialyzed children using recombinant human erythropoietin (Eprex). Results of a French multicenter clinical trial].
    Gagnadoux MF; Loirat C; Berthélémé JP; Maisin A; Kamoun A; Dabout D; Poisson D; Broyer M
    Nephrologie; 1994; 15(3):207-11. PubMed ID: 7969713
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of bolus intraperitoneal iron dextran in continuous ambulatory peritoneal dialysis or continuous cyclic peritoneal dialysis patients receiving recombinant human erythropoietin.
    Mars RL; Moles K; Pope K; Hargrove P
    Adv Perit Dial; 1999; 15():60-4. PubMed ID: 10682073
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A decision analysis comparing three dosage regimens of subcutaneous epoetin in continuous ambulatory peritoneal dialysis.
    Piccoli A; Puggia RM; Fusaro M; Favaro E; Pillon L
    Pharmacoeconomics; 1995 May; 7(5):444-56. PubMed ID: 10155331
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Seizures in haemodialysis patients treated with recombinant human erythropoietin.
    Edmunds ME; Walls J; Tucker B; Baker LR; Tomson CR; Ward M; Cunningham J; Moore R; Winearls CG
    Nephrol Dial Transplant; 1989; 4(12):1065-9. PubMed ID: 2517327
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.